Background
DM1
The antibody–drug conjugate (ADC) trastuzumab emtansine (T-DM1) is composed of the anti-human epidermal growth factor receptor 2 (HER2) antibody trastuzumab linked to the cytotoxic agent DM1 through a stable, uncleavable linker [Pertuzumab is an anti-HER2 antibody that differs from trastuzumab by blocking HER2 dimerization with other HER family members, thereby inhibiting ligand-dependent HER2 signaling [Biomarker analyses could potentially elucidate patient subgroups with better prognosis or with a higher likelihood of clinical benefit from treatment with specific HER2-targeted regimens (e.g., T-DM1 + P vs. TCH + P) in the adjuvant/neoadjuvant setting [